Which medication is listed as an acute adjunctive therapy for bipolar disorder?

• A. Ziprasidone
• B. Fluoxetine/olanzapine combo
• C. Quetiapine
• D. Lurasidone

Answer: (D)

In bipolar depression, adding an antipsychotic to ongoing mood-stabilizing therapy (like lithium or valproate) is a common acute strategy. Lurasidone is the one with explicit labeling as an acute adjunctive therapy to lithium or valproate for bipolar depression, meaning it’s approved to be added on to those mood stabilizers to rapidly address depressive symptoms. It also tends to have a favorable metabolic side-effect profile, which is a helpful consideration in bipolar patients who may be sensitive to weight gain and glucose changes.

The other options are not as clearly defined as adjunctive therapies to mood stabilizers: ziprasidone is mainly used for mania (and some bipolar depression options exist but not the primary adjunct indication), the fluoxetine/olanzapine combination is a fixed-dose antidepressant/antipsychotic treatment for bipolar depression rather than an add-on to a mood stabilizer, and quetiapine is well established for bipolar depression as monotherapy rather than specifically as adjunctive therapy.